Abcellera Biologics Inc. · NASDAQ:ABCL

Abcellera Biologics — Q2 2024 Earnings Presentation

15 slides from Abcellera Biologics's earnings presentation, Aug 6, 2024

  1. Slide 1: Q2 2024 Business Update

    C O P Y R IG H T © A B C E LL E R A Q2 2024 BUSINESS UPDATE AUGUST 6, 2024

  2. Slide 2: Disclaimer

    C O PY R IG H T © A B C EL LE R A DISCLAIMER 2 This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumpt

  3. Slide 3: We are allocating capital across 3 key priorities

    C O PY R IG H T © A B C EL LE R A C O PY R IG H T © A B C EL LE R A 3 Q 2 2 0 2 4 B U S IN ES S U PD AT E We are allocating capital across 3 key priorities. Q 2 2 0 2 4 U P D A T E Engine & Capabilities Strategic Partnerships Internal Programs & Pipeline1 2 3

  4. Slide 4: ABCL635 & ABCL575 are on track for clinical trial applications in Q2 2025

    C O PY R IG H T © A B C EL LE R A C O PY R IG H T © A B C EL LE R A 4 ABCL635 & ABCL575 are on track for clinical trial applications in Q2 2025. O U R P I P E L I N E Q 2 2 0 2 4 B U S IN ES S U PD AT E Molecule Target Indication Therapeutic Area Potential Differentiation ABCL635 undisclosed GPCR or

  5. Slide 5: We are moving four T-cell engager molecules into preclinical efficacy models

    C O PY R IG H T © A B C EL LE R A C O PY R IG H T © A B C EL LE R A 5 We are moving four T-cell engager molecules into preclinical efficacy models. O U R E A R LY I N T E R N A L P R E C L I N I C A L P R O G R A M S Q 2 2 0 2 4 B U S IN ES S U PD AT E Target Potential Indications PSMA x CD3 prostat

  6. Slide 6: Abdera submits IND and receives FDA fast-track designation for ABD-147

    C O PY R IG H T © A B C EL LE R A C O PY R IG H T © A B C EL LE R A 6 O U R P A R T N E R S Q 2 2 0 2 4 B U S IN ES S U PD AT E Abdera submits IND and receives FDA fast-track designation for ABD-147. ABD-147 is a radioisotope antibody conjugate for the treatment of patients with small cell lung canc

  7. Slide 7: Invetx announces upcoming acquisition by Dechra Pharmaceuticals for up to US$520M

    C O PY R IG H T © A B C EL LE R A C O PY R IG H T © A B C EL LE R A 7 O U R P A R T N E R S Q 2 2 0 2 4 B U S IN ES S U PD AT E Invetx announces upcoming acquisition by Dechra Pharmaceuticals for up to US$520M. Invetx has agreed to be acquired by Dechra, a global specialist veterinary pharmaceutical

  8. Slide 8: We recently expanded our strategic collaboration with Lilly

    C O PY R IG H T © A B C EL LE R A C O PY R IG H T © A B C EL LE R A 8 O U R P A R T N E R S Q 2 2 0 2 4 B U S IN ES S U PD AT E We recently expanded our strategic collaboration with Lilly. multiple programs over multiple years 8 de novo programs 1 exclusive license to COVID-19 antibody program IMMUN

  9. Slide 9: Q2 2024 Financials Update

    C O P Y R IG H T © A B C E LL E R A Q2 2024 FINANCIALS UPDATE

  10. Slide 10: Continued progress on key business metrics and a strong cash position

    C O PY R IG H T © A B C EL LE R A C O PY R IG H T © A B C EL LE R A 10 Q 2 2 0 2 4 B U S IN ES S U PD AT E Continued progress on key business metrics and a strong cash position. in total cash, cash equivalents, & marketable securities cumulative partner- initiated program starts with downstreams int

  11. Slide 11: Continuing portfolio growth

    C O PY R IG H T © A B C EL LE R A 14 2 4 6 8 10 12 14 0 19 20 21 22 23 24 Q2 17162015 18 0 10 20 30 40 50 60 70 80 90 100 18 19 20 21 22 23 24 Q2 17162015 93 PARTNER-INITIATED PROGRAM STARTS WITH DOWNSTREAMS Continuing portfolio growth. 11 FI N A N CI A LS Cumulative # of Q 2 2 0 2 4 B U S IN ES S U

  12. Slide 12: Operating expenses reflect ongoing investments, predominantly in R&D

    C O PY R IG H T © A B C EL LE R A Q2 2024Q2 2023 $36.5M $40.9M +$4.5M Q2 2024Q2 2023 $3.8M $3.1M -$0.7M Q2 2024Q2 2023 $15.5M $20.2M +$4.7M 12 FI N A N CI A LS RESEARCH & DEVELOPMENT SALES & MARKETING GENERAL & ADMIN Operating Expenses USD Q 2 2 0 2 4 B U S IN ES S U PD AT E MILESTONES LICENSING RES

  13. Slide 13: Net loss of $37M; ($0.13) per share

    C O PY R IG H T © A B C EL LE R A 13 FI N A N CI A LS Net loss of $37M; equivalent to ($0.13) per share (basic & diluted). NET EARNINGS EARNINGS PER SHARE: BASIC AND DILUTED Q2 2023 Q2 2024 -$30.5M -$36.9M -$0.11 -$0.13 Q2 2023 Q2 2024 Q 2 2 0 2 4 B U S IN ES S U PD AT E Earnings USD

  14. Slide 14: Approximately $700M in total cash, equivalents, and marketable securities

    C O PY R IG H T © A B C EL LE R A 14 FI N A N CI A LS Approximately $700M in total cash, equivalents, and marketable securities. Cash Flows USD Q 2 2 0 2 4 B U S IN ES S U PD AT E INVESTING FINANCING ($31M) Other FX $522M Marketable Securities $148M Cash & Equivalents $627M Marketable Securities Jun

  15. Slide 15: Thank You

    C O PY R IG H T © A B C EL LE R A 15 THANK YOU Q 2 2 0 2 4 B U S IN ES S U PD AT E

AbCellera Biologics — Q2 2024 Earnings Presentation on 6ix